SCHEMBL335303

SCHEMBL335303

CCN(CC)c1ccc(C(=O)NC(c2cc(F)cc(F)c2)C(O)C(=O)Nc2ccc3nc(N)[nH]c3c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
ESRRG P62508 1/20 0.38
F9 P00740 1/20 0.38
F7 P08709 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
F2 P00734 1/20 0.37
F10 P00742 1/20 0.37
PLG P00747 1/20 0.37
PLAU P00749 1/20 0.37
PLAT P00750 1/20 0.37
PRSS1 P07477 1/20 0.37
IKBKB O14920 1/20 0.37
KDR P35968 1/20 0.36
TEK Q02763 1/20 0.36
DHFR P00374 2/20 0.36
GBA1 P04062 1/20 0.36
ATIC P31939 2/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
GART P22102 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335484 0.90 MAPT (0.43) MAPTF9F7SMN1; SMN2IKBKB
SCHEMBL337002 0.90 MAPT (0.41) MAPTESRRGF9F7SMN1; SMN2
SCHEMBL335848 0.89 MCHR1 (0.42) MAPTESRRGF9F7SMN1; SMN2
SCHEMBL336083 0.89 F9 (0.41) MAPTESRRGF9F7SMN1; SMN2
SCHEMBL335904 0.88 MAPT (0.40) MAPTF9F7SMN1; SMN2KDR
SCHEMBL335555 0.88 MAPT (0.39) MAPTESRRGF9F7SMN1; SMN2
SCHEMBL335968 0.88 MAPT (0.41) MAPTESRRGF9F7SMN1; SMN2
SCHEMBL336687 0.87 MAPT (0.39) MAPTF9F7SMN1; SMN2IKBKB
SCHEMBL335732 0.85 MAPT (0.36) MAPTESRRGF9F7SMN1; SMN2
SCHEMBL335959 0.85 MAPT (0.41) MAPTF9F7SMN1; SMN2IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP claimed
US-8097758-B2 Isoserine derivatives for use as coagulation factor IXa inhibitors SANOFI-AVENTIS (FR) 2012-01-17 US claimed
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS TFPI, F2, F9 MAPT 3998/4885ESRRG 4101/4885F9 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.